€120 million of commitments secured

SWORD Health

Sector: Digital Health
Country: Portugal

SWORD Health is a technology company on a mission to improve access to quality, affordable healthcare. The company’s flagship product, SWORD Phoenix, is a sophisticated, comprehensive and user-friendly motor rehabilitation system designed to grant patients access to intensive, task-specific rehabilitation protocols from the comfort of their homes. Rehabilitation is a segment of the healthcare value chain that has remained virtually untouched for the last 50 years and with a aging population is becoming a burden to healthcare systems worldwide. SWORD Phoenix is positioned to disrupt the way rehabilitation is delivered to patients significantly improving outcomes and reducing cost. SWORD Health was founded in 2014 and is led by CEO Virgílio Bento. SWORD Health’s products are used around the world, including the USA, Canada, Australia, Norway, and the company is headquartered in Porto, Portugal.

Contacts

Guy Geldhof, Marc Lohrmann, David Braga Malta

https://www.swordhealth.com/#/

Forendo Pharma

Sector: Drug Development
Country: Finland

Forendo Pharma is a privately held drug development company, with core competences in modulating tissue specific hormone mechanisms. The company was founded in 2013 by leading academic endocrinology experts and Finnish drug development pioneers. Forendo is supported by strong international investors: Novo Seeds, Karolinska Development, Novartis Venture Fund, M Ventures, Innovestor and now Vesalius Biocapital III Partners. The company’s pipeline includes HSD17B1 inhibitor (phase I) for the treatment of endometriosis; dual HSD inhibitors (discovery) for the treatment of broader gynecological conditions; and Fispemifene (phase 2), a novel SERM for the treatment of male urological conditions. Further information is available at www.forendo.com.

Contacts

Risto Lammintausta
CEO, Forendo Pharma Oy
risto.lammintausta@forendo.com
Tel: +358 (0)40 310 8010

Mary Clark, Hollie Vile
Optimum Strategic Communications
healthcare@optimumcomms.com
Tel: +44 (0) 203 714 1788

Mercuris GmbH

Sector: Medtech
Country: Germany

Mecuris teams up with certified prosthetists and orthotists (CPOs) to move orthopaedic care into the digital age. Bringing together 3D technologies into one intuitive Mecuris Solution Platform the company found a way to simplify the CPOs work and transform the way to design and use orthopaedic devices. Mecuris enriches wearers' lives by enabling medical professionals to design their product ideas on our intuitive digital platform - without any CAD design knowledge. This means patients can quickly regain their mobility, show their individuality and become active again faster. Thanks to full CE-mark and ISO certification, Mecuris' products meet the highest safety standards and are reimbursed by all health insurance funds in Germany.

Contacts

Christian Schneider, Managing Partner Vesalius Biocapital
Stéphane Verdood, Managing Partner Vesalius Biocapital

https://www.mecuris.com

DEAR Health

Sector: Digital Health
Country: Netherlands

DEARhealth transforms chronic care towards a quadruple aim: improve patient experience, measurable health outcomes, provider well-being and cost control. The DEARhealth platform and modelling approach enable patient-centric, Artificial Intelligence (AI)-powered health pathways for chronic care. DEARhealth is a health-AI spin-out from the University of California, Los Angeles (UCLA) and has headquarters in Los Angeles and Amsterdam. For more information please visit www.dearhealth.com.

Contacts

Marc Lohrmann, Managing Partner Vesalius Biocapital
Stéphane Verdood, Managing Partner Vesalius Biocapital